39 Active Studies

Anemia Clinical Trials

Find actively recruiting research studies for anemia. Connect with study sites near you and explore new treatment options.

39
Active Trials
144+
Locations
7,119
Participants Needed

Recruiting Studies

RecruitingNCT06520826

Vafseo Outcomes In-Center Experience

This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment ...

5 locations(Lone Tree, Dalton, Gallup)
2,200 participants
USRC Kidney Research
View Study Details
RecruitingNCT06612268

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and ad...

10 locations(Birmingham, Mobile, Phoenix)
408 participants
Novo Nordisk A/S
View Study Details
RecruitingNCT05949684

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve part...

10 locations(Clovis, Fountain Valley, Fresno)
360 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT06901505

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimu...

10 locations(Montgomery, Hartford, Middlebury)
350 participants
Akebia Therapeutics
View Study Details
RecruitingNCT06609226

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect ha...

10 locations(Birmingham, Phoenix, Los Angeles)
325 participants
Novo Nordisk A/S
View Study Details
RecruitingNCT06439082

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide ther...

10 locations(Washington D.C., Jacksonville, Augusta)
315 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT06290401

A Socio-ecological Approach for Improving Self-management in Adolescents With SCD

The goal of this clinical trial is to evaluate the impact of SCThrive (a behavioral self-management intervention) on patient activation, self-management behaviors, daily functioning, and emergency roo...

4 locations(Wilmington, Atlanta, Cincinnati)
310 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingNCT05462704

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<3...

8 locations(Birmingham, Miami, Ann Arbor)
300 participants
Women and Infants Hospital of Rhode Island
View Study Details
RecruitingNCT05600426

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatme...

10 locations(Birmingham, Phoenix, Little Rock)
234 participants
Boston Children's Hospital
View Study Details
RecruitingNCT06499285

The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)

This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk...

10 locations(Duarte, La Jolla, Canton)
225 participants
Takeda
View Study Details
RecruitingNCT06481306

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and partic...

10 locations(Birmingham, La Jolla, Oakland)
184 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05320198

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofi...

10 locations(Jacksonville, Ann Arbor, Rochester)
150 participants
Disc Medicine, Inc
View Study Details
RecruitingNCT04419649

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS....

10 locations(Duarte, Miami, Tampa)
140 participants
Takeda
View Study Details
RecruitingNCT04657822

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored s...

10 locations(Birmingham, Washington D.C., Augusta)
130 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT03619850

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA ...

10 locations(Hollywood, Detroit, Kansas City)
129 participants
AMAG Pharmaceuticals, Inc.
View Study Details
RecruitingNCT01174108

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Background: * Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemi...

2 locations(Baltimore, Bethesda)
120 participants
National Heart, Lung, and Blood Institute (NHLBI)
View Study Details
RecruitingNCT05929729

Iron Deficiency Anemia (IDA) and the Brain

This is a trial with an observational and an interventional arm, in patients with moderate to severe anemia and control subjects. The main purposes of this study is to phenotype the scope of neurocogn...

4 locations(Duarte, Los Angeles, Los Angeles)
120 participants
Children's Hospital Los Angeles
View Study Details
RecruitingNCT05912517

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below...

10 locations(Los Angeles, Sacramento, Aurora)
120 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT04119050

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA)....

10 locations(Fountain Valley, Los Angeles, Riverside)
111 participants
Janssen Research & Development, LLC
View Study Details
RecruitingNCT03587272

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyelo...

7 locations(Washington D.C., Chicago, New York)
100 participants
Robert Nickel
View Study Details
RecruitingNCT05648968

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment....

10 locations(Aurora, Margate, Evanston)
90 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT05490446

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participant...

10 locations(Lakewood, Los Angeles, Redlands)
82 participants
Agios Pharmaceuticals, Inc.
View Study Details
RecruitingNCT03893045

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt by their clinician to be at risk of developing IDA....

10 locations(Little Rock, Gainesville, Miami)
75 participants
AMAG Pharmaceuticals, Inc.
View Study Details
RecruitingNCT02143830

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi A...

3 locations(New York, Cincinnati, Seattle)
70 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingNCT06665997

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease. Part...

2 locations(Atlanta, Philadelphia)
65 participants
University of Pennsylvania
View Study Details
RecruitingNCT06517641

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated....

10 locations(Birmingham, Duarte, Los Angeles)
60 participants
Medical College of Wisconsin
View Study Details
RecruitingNCT06924970

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD....

8 locations(Farmington, Washington D.C., New York)
56 participants
Agios Pharmaceuticals, Inc.
View Study Details
RecruitingNCT02675959

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoi...

4 locations(Los Angeles, Gainesville, Valhalla)
40 participants
New York Medical College
View Study Details
RecruitingNCT03991169

Oral Iron in Children With Chronic Kidney Disease

This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs. n...

2 locations(New York, Philadelphia)
40 participants
Weill Medical College of Cornell University
View Study Details
RecruitingNCT06430788

A Study of Emapalumab for Pediatric Aplastic Anemia

The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Fundin...

6 locations(New York, Cincinnati, Philadelphia)
35 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNCT05861453

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients with Sickle Cell Disease

To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years....

10 locations(Birmingham, Farmington, Washington D.C.)
30 participants
Afimmune
View Study Details
RecruitingNCT05477563

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologou...

6 locations(New York, Charlotte, Nashville)
26 participants
Vertex Pharmaceuticals Incorporated
View Study Details
RecruitingNCT05736419

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers t...

6 locations(Basking Ridge, Middletown, Montvale)
24 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNCT02447874

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrea...

2 locations(Atlanta, Atlanta)
21 participants
Emory University
View Study Details
RecruitingNCT02828592

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients...

2 locations(Atlanta, Atlanta)
20 participants
Northside Hospital, Inc.
View Study Details
RecruitingNCT05329649

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9...

7 locations(Charlotte, Philadelphia, Memphis)
15 participants
Vertex Pharmaceuticals Incorporated
View Study Details
RecruitingNCT04819841

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate sa...

3 locations(Palo Alto, St Louis, Columbus)
15 participants
Kamau Therapeutics
View Study Details
RecruitingNCT05456880

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD...

10 locations(Birmingham, Phoenix, Palo Alto)
15 participants
Beam Therapeutics Inc.
View Study Details
RecruitingNCT04774536

Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease

This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjec...

2 locations(Los Angeles, Oakland)
9 participants
Mark Walters, MD
View Study Details

Frequently Asked Questions

What clinical trials are available for Anemia?

There are currently 39 actively recruiting clinical trials for anemia. These studies are testing new treatments, therapies, and interventions at research sites across 144 cities.

How do I join a Anemia clinical trial?

To join a anemia clinical trial: 1) Browse the available studies above, 2) Click on a study that interests you, 3) Complete the eligibility form, and 4) A study coordinator will contact you.

Are clinical trials free for patients?

Yes, clinical trial participation is free. In most studies, the treatment, medical tests, and doctor visits related to the trial are provided at no cost. Some studies may also compensate for time and travel.

Can I leave a clinical trial if I change my mind?

Yes, participation in any clinical trial is completely voluntary. You can withdraw at any time, for any reason, without affecting your regular medical care.